CAPE COD BIOLAB CORPORATION – Trademark Portfolio
Entity Type: 03
CAPE COD BIOLAB CORPORATION holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 30 (Staple Foods) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CRAN-MAX. The owner is based in BUZZARDS BAY, MA.
PO BOX 777
BUZZARDS BAY, MA 025320777
Showing of trademarks Trademarks
Trademark Classifications
CAPE COD BIOLAB CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Frequently Asked Questions
How many trademarks does CAPE COD BIOLAB CORPORATION have?
CAPE COD BIOLAB CORPORATION has 9 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 abandoned, 3 cancelled.
What trademark classes does CAPE COD BIOLAB CORPORATION file in?
CAPE COD BIOLAB CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 30 (Staple Foods), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CAPE COD BIOLAB CORPORATION's most well-known trademarks?
CAPE COD BIOLAB CORPORATION's registered trademark portfolio includes well-known marks such as CRAN-MAX. These are among 1 currently registered trademark in the portfolio.
What is CAPE COD BIOLAB CORPORATION's trademark registration success rate?
CAPE COD BIOLAB CORPORATION has a 11% trademark registration rate, with 1 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.